BioSpace News Archive

Innovative Health Diagnostics (IHD), announced today a new partnership with AIMA Laboratories (AIMA), a preclinical FemTech company dedicated to developing new products that fill current gaps in gynecological health, to develop and deliver a new and reliable at-home blood test to detect endometriosis.

Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that recombinant trypsinogen and chmyotrypsinogen were synthesized via the Proenzyme Optimization Project (POP1) joint research and drug discovery program.

By End User, Diagnostic Laboratories And Hospitals Are Expected To Remain Dominant In Antimicrobial Susceptibility Test Market During Forecast Period.

Spineology Inc. , the longtime leader in ultra-minimally invasive spine surgery, today announced the appointment of Jamison Young to the position of Chief Financial Officer.

Wilmington, Delaware, United States, Transparency Market Research Inc. – The global orthokeratology market is expected to grow at a favorable rate from 2021 to 2031 (forecast period).

Wilmington, Delaware, United States, Transparency Market Research Inc. – Overactive bladder treatment includes various therapies used to treat the sudden, involuntary contraction of the muscle in the urinary bladder wall.

ValnevaSE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, confirms today that the World Health Organization (WHO) has issued recommendations for use of the Company’s inactivated COVID-19 vaccine.

Integra LifeSciences Holdings Corporation, a leading global medical technology company, announced that it is participating in the following investor conferences:

After successfully completing in vitro and in vivo (mice) experiments, which support the notion that its lead drug candidate OM-301 breaks down cancer cells and significantly increases survival rates, Oncolyze now has its sights set on advancing OM-301 into clinical trials.

The global Immune thrombocytopenia market was valued at USD 2.18 billion in 2019 and is expected to reach USD 3.68 billion by the year 2027, at a CAGR of 6.7%